Published in Br J Cancer on March 02, 2001
Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma. J Clin Endocrinol Metab (2007) 1.60
Neuroendocrine markers in adenocarcinomas: an investigation of 356 cases. World J Gastroenterol (2003) 0.95
Advances in biochemical screening for phaeochromocytoma using biogenic amines. Clin Biochem Rev (2009) 0.87
Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis. PLoS One (2015) 0.84
Aace/Ace disease state clinical review: diagnosis and management of midgut carcinoids. Endocr Pract (2015) 0.76
Chromogranin A Regulation of Obesity and Peripheral Insulin Sensitivity. Front Endocrinol (Lausanne) (2017) 0.75
Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med (1986) 1.58
Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma. Eur J Endocrinol (1997) 1.53
Serum neuron-specific enolase. A marker for disease extent and response to therapy for small-cell lung cancer. Chest (1985) 1.44
Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab (1997) 1.38
Biochemistry of the chromogranin A protein family. Biochem J (1989) 1.35
Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev (1991) 1.29
Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer (1998) 1.23
The primary structure of human chromogranin A and pancreastatin. J Biol Chem (1987) 1.22
Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer. Br J Cancer (1993) 1.15
Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. N Engl J Med (1984) 1.14
Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine (Baltimore) (1991) 1.14
Intracellular and extracellular processing of chromogranin A. Determination of cleavage sites. Eur J Biochem (1993) 1.08
Antibacterial activity of glycosylated and phosphorylated chromogranin A-derived peptide 173-194 from bovine adrenal medullary chromaffin granules. J Biol Chem (1996) 1.06
Adrenocortical tumors: recent advances in basic concepts and clinical management. Ann Intern Med (1999) 1.05
Chromogranin A: posttranslational modifications in secretory granules. Endocrinology (1991) 1.04
Elevated serum chromogranin A concentrations in small-cell lung carcinoma. Ann Intern Med (1986) 1.03
A polyclonal antiserum against chromogranin A and B--a new sensitive marker for neuroendocrine tumours. Acta Endocrinol (Copenh) (1990) 1.02
Human chromogranin A. Purification and characterization from catecholamine storage vesicles of human pheochromocytoma. Hypertension (1984) 1.02
Chromogranin A: its clinical value as marker of neuroendocrine tumours. Eur J Clin Invest (1998) 1.02
The granin protein family: markers for neuroendocrine cells and tools for the diagnosis of neuroendocrine tumors. J Endocrinol Invest (1994) 0.96
Chromogranin A in children with neuroblastoma. Serum concentration parallels disease stage and predicts survival. J Clin Invest (1990) 0.93
Hormone-negative, chromogranin A-positive endocrine tumors. N Engl J Med (1989) 0.93
Neuroendocrine differentiation in adrenocortical carcinoma. New immunohistochemical findings supported by electron microscopy. Lab Invest (1992) 0.91
Plasma catecholamines in hypertension and pheochromocytoma determined using ion-pair reversed-phase chromatography with amperometric detection: investigation of the separation mechanism and clinical methodology. J Chromatogr (1981) 0.91
Chromogranin A: a multipurpose prohormone? Acta Physiol Scand (1994) 0.87
A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245). Br J Cancer (1999) 0.87
Characterisation of circulating chromogranin A in human cancer patients. Br J Cancer (1996) 0.86
Chromogranin A as tumor marker in medullary thyroid carcinoma. Thyroid (1992) 0.86
Chromogranin A and B and secretogranin II in bronchial and intestinal carcinoids. Virchows Arch A Pathol Anat Histopathol (1987) 0.85
Enzyme-linked immunosorbent assay for chromogranin A. Clin Chem (1989) 0.83
Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia. Neuropeptides (1994) 0.83
Neuroendocrine differentiation and nerves in human adrenal cortex and cortical lesions. APMIS (1998) 0.82
Chromogranin A in familial pheochromocytoma: diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution. Am J Med (1990) 0.81
Chromogranin A measurement in neuroendocrine tumors. Int J Biol Markers (1998) 0.81
Immunohistochemical demonstration of chromogranins A and B in neuroendocrine tumors of the lung. Hum Pathol (1992) 0.81
Demonstration of Chromogranin A in human neuroendocrine cell lines by immunohistology and immunoassay. Cancer (1988) 0.81
Plasma chromogranin A in pheochromocytoma, primary hyperparathyroidism and pituitary adenoma in comparison with catecholamine, parathyroid hormone and pituitary hormones. Endocr J (1997) 0.80
Immunoluminometric assay of chromogranin A in serum with commercially available reagents. Clin Chem (1992) 0.77
Plasma chromogranin A + B, neuropeptide Y and catecholamines in pheochromocytoma patients. J Intern Med (1991) 0.77
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol (2002) 3.75
Age-related reduction of NO availability and oxidative stress in humans. Hypertension (2001) 3.37
Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation (1995) 3.19
Physical activity prevents age-related impairment in nitric oxide availability in elderly athletes. Circulation (2000) 2.57
Are reactive oxygen species involved in Alzheimer's disease? Neurobiol Aging (1996) 2.47
Benign infantile familial convulsions. Eur J Pediatr (1992) 2.46
Association between hepatitis C virus and mixed cryoglobulinemia [see comment]. Clin Exp Rheumatol (1992) 2.43
Diversity of the Chlamydia trachomatis common plasmid in biovars with different pathogenicity. Plasmid (1990) 2.19
Detection of c-Ki-ras mutation by PCR/RFLP analysis and diagnosis of pancreatic adenocarcinomas. J Natl Cancer Inst (1993) 2.16
Broadband observations of the naked-eye gamma-ray burst GRB 080319B. Nature (2008) 2.16
Office varicose vein surgery under local anesthesia. J Dermatol Surg Oncol (1992) 2.01
Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation (1996) 1.98
Anti-inflammatory effect of exercise training in subjects with type 2 diabetes and the metabolic syndrome is dependent on exercise modalities and independent of weight loss. Nutr Metab Cardiovasc Dis (2009) 1.95
Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol (2001) 1.94
Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation (1998) 1.86
Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J Immunol (1998) 1.75
Hypertension causes premature aging of endothelial function in humans. Hypertension (1997) 1.70
Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clin Endocrinol (Oxf) (2007) 1.66
Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment. J Med Genet (2005) 1.63
Cross-resistance between methicillin and cephalosporins for staphylococci: a general assumption not true for cefamandole. Antimicrob Agents Chemother (1984) 1.61
Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann Oncol (1997) 1.61
Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension (1993) 1.60
Menopause is associated with endothelial dysfunction in women. Hypertension (1996) 1.59
Sympathetic nervous system-dependent vasoconstriction in humans. Evidence for mechanistic role of endogenous purine compounds. Circulation (1990) 1.58
Evolution of clinical behaviour in Crohn's disease: predictive factors of penetrating complications. Dig Liver Dis (2005) 1.58
Insulin sensitivity, vascular reactivity, and clamp-induced vasodilatation in essential hypertension. Circulation (1997) 1.53
Plasma endothelin-1 concentrations in patients with retinal vein occlusions. Br J Ophthalmol (1998) 1.53
Guillain-Barré syndrome after exogenous gangliosides in Italy. BMJ (1993) 1.52
Digestive neuroendocrine tumours: diagnosis and treatment in Italy. A survey by the Oncology Study Section of the Italian Society of Gastroenterology (SIGE). Dig Liver Dis (2001) 1.50
Comparability and validity of two clinical scores in the early differential diagnosis of acute stroke. BMJ (1994) 1.49
Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. Arthritis Rheum (1991) 1.49
Autonomous thyroid nodule and percutaneous ethanol injection. Lancet (1991) 1.48
Characterization of mutations in the gene doublecortin in patients with double cortex syndrome. Ann Neurol (1999) 1.47
Enhanced cardiac contractility after gene transfer of V2 vasopressin receptors In vivo by ultrasound-guided injection or transcoronary delivery. Circulation (2000) 1.45
doublecortin is the major gene causing X-linked subcortical laminar heterotopia (SCLH). Hum Mol Genet (1998) 1.44
The structure of a plasmid of Chlamydia trachomatis believed to be required for growth within mammalian cells. Mol Microbiol (1988) 1.44
Expression of a plasmid gene of Chlamydia trachomatis encoding a novel 28 kDa antigen. J Gen Microbiol (1993) 1.44
Gene transfer of heterologous G protein-coupled receptors to cardiomyocytes: differential effects on contractility. Circ Res (2001) 1.42
Plasma and tissue chromogranin in patients with adrenocortical adenomas. J Endocrinol Invest (2004) 1.42
Normal volumetric bone mineral density and bone turnover in young men with histories of constitutional delay of puberty. J Clin Endocrinol Metab (1998) 1.42
Percutaneous ethanol injection treatment of autonomous thyroid adenoma: hormonal and clinical evaluation. Clin Endocrinol (Oxf) (1992) 1.41
The "T" vein of the leg. Dermatol Surg (2004) 1.40
Phylogeny and evolution of Orchis and allied genera based on ITS DNA variation: morphological gaps and molecular continuity. Mol Phylogenet Evol (1999) 1.39
An unexpectedly rapid decline in the X-ray afterglow emission of long gamma-ray bursts. Nature (2005) 1.39
Presence of cardiovascular structural changes in essential hypertensive patients with coronary microvascular disease and effects of long-term treatment. Am J Hypertens (1996) 1.38
Beauvericin production by Fusarium species. Appl Environ Microbiol (1998) 1.37
Genome organization of the killer plasmid pGK12 from Kluyveromyces lactis. Nucleic Acids Res (1988) 1.36
The association of GRB 060218 with a supernova and the evolution of the shock wave. Nature (2006) 1.32
A short gamma-ray burst apparently associated with an elliptical galaxy at redshift z = 0.225. Nature (2005) 1.32
Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol (1999) 1.27
Functional diversity of P-type and R-type calcium channels in rat cerebellar neurons. J Neurosci (1996) 1.26
Selective arterial embolization in the treatment of aneurysmal bone cyst and angioma of bone. Skeletal Radiol (1992) 1.25
Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients. Eur J Clin Pharmacol (1982) 1.24
Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension. Hypertension (1997) 1.24
Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated rep-cap genome. J Gene Med (2000) 1.23
Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer (2006) 1.22
["Prolonged" decay test and auditory brainstem responses in the clinical diagnosis of the chronic fatigue syndrome]. Acta Otorhinolaryngol Ital (1996) 1.20
Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension (2000) 1.19
Obesity in the childhood: a link to adult hypertension. Curr Pharm Des (2009) 1.18
Three-dimensional contrastless varicography by spiral computed tomography. Eur J Vasc Endovasc Surg (2001) 1.18
Novel cis-acting replication element in the adeno-associated virus type 2 genome is involved in amplification of integrated rep-cap sequences. J Virol (2001) 1.16
Control of erythropoietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector. Blood (1998) 1.16
Blocking caspase-activated apoptosis improves contractility in failing myocardium. Hum Gene Ther (2001) 1.15
Mechanisms responsible for endothelial dysfunction associated with acute estrogen deprivation in normotensive women. Circulation (2000) 1.14
Thyroidal and peripheral production of 3,5,3'-triiodothyronine in humans by multicompartmental analysis. Am J Physiol (1990) 1.13
Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol (2000) 1.12
Cardiovascular disease and osteoporosis. J Endocrinol Invest (2005) 1.12
Effect of caroxazone, a new antidepressant drug, on monoamine oxidases in healthy volunteers. Br J Clin Pharmacol (1981) 1.11
First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Ann Oncol (2004) 1.11
Occurrence and toxicity of Fusarium subglutinans from Peruvian maize. Mycopathologia (1993) 1.10
Soluble E-selectin in essential hypertension: a correlate of vascular structural changes. Am J Hypertens (2001) 1.10
Suction skin blister, skin window, and skin chamber techniques to determine extravascular passage of cefotaxime in humans. Antimicrob Agents Chemother (1981) 1.10
Subthalamic nucleus stimulation in Parkinson's disease : anatomical and electrophysiological localization of active contacts. J Neurol (2006) 1.10
Endogenous androgens and carotid intimal-medial thickness in women. J Clin Endocrinol Metab (1999) 1.10
The joint of Tn916 circular intermediates is a homoduplex in Enterococcus faecalis. Plasmid (1997) 1.10
A novel chromatin-forming histone H1 homologue is encoded by a dispensable and growth-regulated gene in Bordetella pertussis. Mol Microbiol (1995) 1.09
Hepatitis C virus antibodies in mixed cryoglobulinemia. Clin Exp Rheumatol (1991) 1.09
High prevalence of undiagnosed coeliac disease in 5280 Italian students screened by antigliadin antibodies. Acta Paediatr (1995) 1.09
Role of neck ultrasonography in the follow-up of patients operated on for thyroid cancer. Thyroid (1995) 1.08
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br J Cancer (2011) 1.08
Endothelium-dependent forearm vasodilation is reduced in normotensive subjects with familial history of hypertension. J Cardiovasc Pharmacol (1992) 1.07
UGT1 promoter polymorphism accounts for increased neonatal appearance of hereditary spherocytosis. Blood (1998) 1.07
Epicardial adipose tissue adiponectin expression is related to intracoronary adiponectin levels. Horm Metab Res (2008) 1.07
Dosage of Tn916 circular intermediates in Enterococcus faecalis. Plasmid (1995) 1.06
Spinal cord injury in Italy: A multicenter retrospective study. Arch Phys Med Rehabil (2001) 1.06
18F-FDG PET/CT in the assessment of carcinoma of unknown primary origin. Radiol Med (2006) 1.06
Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients. J Hypertens (2001) 1.06
Age- and peroxidative stress-related modifications of the cerebral enzymatic activities linked to mitochondria and the glutathione system. Free Radic Biol Med (1995) 1.05
Genetic and neuroradiological heterogeneity of double cortex syndrome. Ann Neurol (2000) 1.05
Relationship between the fungal complex causing Fusarium head blight of wheat and environmental conditions. Phytopathology (2008) 1.05
Mutations in dynein genes in patients affected by isolated non-syndromic asthenozoospermia. Hum Reprod (2008) 1.03
Orbital exenteration in elderly patients: personal experience. Acta Otorhinolaryngol Ital (2008) 1.03
Noninvasive molecular tracking of colonizing wolf (Canis lupus) packs in the western Italian Alps. Mol Ecol (2002) 1.03
Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int J Clin Pract (2008) 1.03
Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension (2001) 1.03